Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Handelsbanken Fonder AB

Handelsbanken Fonder AB grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 59.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 100,706 shares of the biopharmaceutical company’s stock after purchasing an additional 37,657 shares during the period. Handelsbanken Fonder AB’s holdings in Regeneron Pharmaceuticals were worth $77,732,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the business. TD Private Client Wealth LLC increased its holdings in shares of Regeneron Pharmaceuticals by 9.7% during the fourth quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 15 shares during the period. Meyer Handelman Co. raised its stake in shares of Regeneron Pharmaceuticals by 0.6% in the 4th quarter. Meyer Handelman Co. now owns 2,878 shares of the biopharmaceutical company’s stock worth $2,221,000 after buying an additional 18 shares in the last quarter. Gateway Investment Advisers LLC raised its stake in shares of Regeneron Pharmaceuticals by 4.3% in the 4th quarter. Gateway Investment Advisers LLC now owns 464 shares of the biopharmaceutical company’s stock worth $358,000 after buying an additional 19 shares in the last quarter. MGO One Seven LLC raised its stake in shares of Regeneron Pharmaceuticals by 3.3% in the 4th quarter. MGO One Seven LLC now owns 589 shares of the biopharmaceutical company’s stock worth $455,000 after buying an additional 19 shares in the last quarter. Finally, Whittier Trust Co. raised its stake in shares of Regeneron Pharmaceuticals by 5.9% in the 4th quarter. Whittier Trust Co. now owns 357 shares of the biopharmaceutical company’s stock worth $277,000 after buying an additional 20 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, May 1st. The stock was sold at an average price of $705.24, for a total transaction of $70,524.00. Following the transaction, the director owned 17,503 shares in the company, valued at approximately $12,343,815.72. The trade was a 0.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 1,638 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the transaction, the director owned 1,703 shares in the company, valued at $1,330,604.99. This represents a 49.03% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $629.68 on Tuesday. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $66.57 billion, a price-to-earnings ratio of 15.34, a PEG ratio of 1.55 and a beta of 0.30. The stock’s fifty day simple moving average is $741.98 and its 200 day simple moving average is $745.92. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.48 billion. During the same period in the previous year, the firm posted $8.22 EPS. The company’s quarterly revenue was up 19.0% on a year-over-year basis. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.1 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th will be issued a dividend of $0.94 per share. The ex-dividend date is Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is currently 9.16%.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of research reports. Sanford C. Bernstein dropped their price objective on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 8th. Barclays dropped their price objective on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Cantor Fitzgerald reissued an “overweight” rating and issued a $800.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday, April 23rd. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, March 27th. Finally, Guggenheim boosted their price objective on Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a “buy” rating in a research note on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $800.57.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Negative Sentiment: Regeneron’s Phase 3 melanoma trial did not show statistically significant improvement on its main goal, disappointing expectations for a key cancer drug candidate. Reuters article
• Negative Sentiment: The trial failure triggered a wave of analyst caution and multiple price target cuts, reflecting reduced confidence in near-term pipeline upside. Proactive Investors article
• Negative Sentiment: Law firms have started investigating whether Regeneron and its executives made overly optimistic statements about the melanoma program before the disappointing results were disclosed. PR Newswire article
• Neutral Sentiment: Regeneron also announced a strategic collaboration with Parabilis Medicines to develop Antibody-Helicon™ Conjugates, which could broaden its pipeline, but the partnership is still early-stage and carries execution risk. GlobeNewswire article

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.